Literature DB >> 30418595

Novel methods to diagnose leptomeningeal metastases in breast cancer.

Lindsay Angus1, John W M Martens1, Martin J van den Bent2, Peter A E Sillevis Smitt2, Stefan Sleijfer1, Agnes Jager1.   

Abstract

Leptomeningeal metastases (LM) in breast cancer patients are rare but often accompanied by devastating neurological symptoms and carry a very poor prognosis, even if treated. To date, two diagnostic methods are clinically used to diagnose LM: gadolinium MRI of the brain and/or spinal cord and cytological examination of cerebrospinal fluid (CSF). Both techniques are, however, hampered by limited sensitivities, often leading to a long diagnostic process requiring repeated lumbar punctures and MRI examinations. To improve the detection rate of LM, numerous studies have assessed new techniques. In this review, we present the current workup to diagnose LM, set out an overview of novel techniques to diagnose LM, and give recommendations for future research.
© The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  biomarkers; breast cancer; cerebrospinal fluid; leptomeningeal metastases

Mesh:

Year:  2019        PMID: 30418595      PMCID: PMC6422430          DOI: 10.1093/neuonc/noy186

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  62 in total

1.  Meningeal carcinomatosis in breast cancer: prognostic factors and outcome.

Authors:  Carla Rameri Alexandre Silva de Azevedo; Marcelo Rocha Sousa Cruz; Ludmilla Thomé Domingos Chinen; Stela Verzinhasse Peres; Marcos Aurélio Peterlevitz; Artur Eugênio de Azevedo Pereira; Marcello Ferretti Fanelli; Daniel Luiz Gimenes
Journal:  J Neurooncol       Date:  2011-01-14       Impact factor: 4.130

2.  CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases.

Authors:  J C Reijneveld; D Brandsma; W Boogerd; J G M Bonfrer; S Kalmijn; E E Voest; A Geurts-Moespot; M C Visser; M J B Taphoorn
Journal:  Neurology       Date:  2005-10-11       Impact factor: 9.910

3.  Creatine kinase-BB in the cerebrospinal fluid as a marker of CNS metastases and leptomeningeal carcinomatosis in patients with breast cancer.

Authors:  F Bach; F W Bach; A G Pedersen; P M Larsen; P Dombernowsky
Journal:  Eur J Cancer Clin Oncol       Date:  1989-12

4.  Cerebrospinal fluid beta 2-microglobulin: a study in controls and patients with metastatic and non-metastatic neurological diseases.

Authors:  A Twijnstra; A P van Zanten; W J Nooyen; A A Hart; B W Ongerboer de Visser
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04

5.  Methylation of the hTERT promoter: a novel cancer biomarker for leptomeningeal metastasis detection in cerebrospinal fluids.

Authors:  Stéphanie Bougel; Benoit Lhermitte; Gabrielle Gallagher; Jeanne-Chantal de Flaugergues; Robert C Janzer; Jean Benhattar
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

6.  Serial lumbar and ventricle cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumours.

Authors:  A Twijnstra; A P van Zanten; A A Hart; B W Ongerboer de Visser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-03       Impact factor: 10.154

7.  Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancer.

Authors:  M Fleisher; W R Wasserstrom; S C Schold; M K Schwartz; J B Posner
Journal:  Cancer       Date:  1981-06-01       Impact factor: 6.860

8.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

Authors:  Priscilla K Brastianos; Scott L Carter; Gad Getz; William C Hahn; Sandro Santagata; Daniel P Cahill; Amaro Taylor-Weiner; Robert T Jones; Eliezer M Van Allen; Michael S Lawrence; Peleg M Horowitz; Kristian Cibulskis; Keith L Ligon; Josep Tabernero; Joan Seoane; Elena Martinez-Saez; William T Curry; Ian F Dunn; Sun Ha Paek; Sung-Hye Park; Aaron McKenna; Aaron Chevalier; Mara Rosenberg; Frederick G Barker; Corey M Gill; Paul Van Hummelen; Aaron R Thorner; Bruce E Johnson; Mai P Hoang; Toni K Choueiri; Sabina Signoretti; Carrie Sougnez; Michael S Rabin; Nancy U Lin; Eric P Winer; Anat Stemmer-Rachamimov; Matthew Meyerson; Levi Garraway; Stacey Gabriel; Eric S Lander; Rameen Beroukhim; Tracy T Batchelor; Jose Baselga; David N Louis
Journal:  Cancer Discov       Date:  2015-09-26       Impact factor: 39.397

9.  Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors.

Authors:  Lakshmi Nayak; Martin Fleisher; Rita Gonzalez-Espinoza; Oscar Lin; Katherine Panageas; Anne Reiner; Chhui-Mei Liu; Lisa M Deangelis; Antonio Omuro
Journal:  Neurology       Date:  2013-04-03       Impact factor: 9.910

10.  Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis.

Authors:  Emilie Le Rhun; Frédéric Massin; Qian Tu; Jacques Bonneterre; Marcelo De Carvalho Bittencourt; Gilbert C Faure
Journal:  BMC Clin Pathol       Date:  2012-11-12
View more
  6 in total

Review 1.  Breast leptomeningeal disease: a review of current practices and updates on management.

Authors:  Nicholas B Figura; Victoria T Rizk; Avan J Armaghani; John A Arrington; Arnold B Etame; Hyo S Han; Brian J Czerniecki; Peter A Forsyth; Kamran A Ahmed
Journal:  Breast Cancer Res Treat       Date:  2019-06-17       Impact factor: 4.872

2.  The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer.

Authors:  Yong Wang; Ningning Luo; Ye Gao; Yaqing Wu; Xueting Qin; Yingxue Qi; Tingting Sun; Rongjie Tao; Chuang Qi; Baoyan Liu; Shuanghu Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-18       Impact factor: 4.553

3.  Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review.

Authors:  Leonor Fernandes; Leonor Vasconcelos de Matos; Débora Cardoso; Marlene Saraiva; Renata Medeiros-Mirra; Andreia Coelho; Helena Miranda; Ana Martins
Journal:  CNS Oncol       Date:  2020-10-20

4.  Autocrine GMCSF Signaling Contributes to Growth of HER2+ Breast Leptomeningeal Carcinomatosis.

Authors:  Khairul I Ansari; Arunoday Bhan; Mika Saotome; Antariksh Tyagi; Bony De Kumar; Clara Chen; Motoki Takaku; Rahul Jandial
Journal:  Cancer Res       Date:  2021-07-09       Impact factor: 12.701

Review 5.  Management of Brain and Leptomeningeal Metastases from Breast Cancer.

Authors:  Alessia Pellerino; Valeria Internò; Francesca Mo; Federica Franchino; Riccardo Soffietti; Roberta Rudà
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

6.  Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.

Authors:  Bart K Chwalisz; James Hillis; Amanda C Guidon; Leeann B Burton; Teilo H Schaller; Anthony A Amato; Allison Betof Warner; Priscilla K Brastianos; Tracey A Cho; Stacey L Clardy; Justine V Cohen; Jorg Dietrich; Michael Dougan; Christopher T Doughty; Divyanshu Dubey; Jeffrey M Gelfand; Jeffrey T Guptill; Douglas B Johnson; Vern C Juel; Robert Kadish; Noah Kolb; Nicole R LeBoeuf; Jenny Linnoila; Andrew L Mammen; Maria Martinez-Lage; Meghan J Mooradian; Jarushka Naidoo; Tomas G Neilan; David A Reardon; Krista M Rubin; Bianca D Santomasso; Ryan J Sullivan; Nancy Wang; Karin Woodman; Leyre Zubiri; William C Louv; Kerry L Reynolds
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.